Newly Discovered Polymorphism May Have Immediate Impact in HCV
This article was originally published in Start Up
Executive Summary
It's extraordinarily rare for a biomarker discovery to have a fast, clear-cut, and significant impact on a therapeutic area. But recent findings from a hepatitis C study--that a specific genetic variation strongly correlates with response to standard interferon-based therapy--could influence decision-making on when and how to treat certain HCV patients. What's more, the research may influence the design of clinical trials of new HCV agents and even trials in other diseases treated with interferon.